Deep Learning and Medical Imaging for COVID-19 Diagnosis: A Comprehensive Survey

COVID-19 (Coronavirus disease 2019) has been quickly spreading since its outbreak, impacting financial markets and healthcare systems globally. Countries all around the world have adopted a number of extraordinary steps to restrict the spreading virus, where early COVID-19 diagnosis is essential. Medical images such as X-ray images and Computed Tomography scans are becoming one of the main diagnostic tools to combat COVID-19 with the aid of deep learning-based systems. In this survey, we investigate the main contributions of deep learning applications using medical images in fighting against COVID-19 from the aspects of image classification, lesion localization, and severity quantification, and review different deep learning architectures and some image preprocessing techniques for achieving a preciser diagnosis. We also provide a summary of the X-ray and CT image datasets used in various studies for COVID-19 detection. The key difficulties and potential applications of deep learning in fighting against COVID-19 are finally discussed. This work summarizes the latest methods of deep learning using medical images to diagnose COVID-19, highlighting the challenges and inspiring more studies to keep utilizing the advantages of deep learning to combat COVID-19

A comparative analysis of chronic obstructive pulmonary disease using machine learning, and deep learning

Chronic obstructive pulmonary disease (COPD) is a general clinical issue in numerous countries considered the fifth reason for inability and the third reason for mortality on a global scale within 2021. From recent reviews, a deep convolutional neural network (CNN) is used in the primary analysis of the deadly COPD, which uses the computed tomography (CT) images procured from the deep learning tools. Detection and analysis of COPD using several image processing techniques, deep learning models, and machine learning models are notable contributions to this review. This research aims to cover the detailed findings on pulmonary diseases or lung diseases, their causes, and symptoms, which will help treat infections with high performance and a swift response. The articles selected have more than 80% accuracy and are tabulated and analyzed for sensitivity, specificity, and area under the curve (AUC) using different methodologies. This research focuses on the various tools and techniques used in COPD analysis and eventually provides an overview of COPD with coronavirus disease 2019 (COVID-19) symptoms.

LDDNet: a deep learning framework for the diagnosis of infectious lung diseases.

This paper proposes a new deep learning (DL) framework for the analysis of lung diseases, including COVID-19 and pneumonia, from chest CT scans and X-ray (CXR) images. This framework is termed optimized DenseNet201 for lung diseases (LDDNet). The proposed LDDNet was developed using additional layers of 2D global average pooling, dense and dropout layers, and batch normalization to the base DenseNet201 model. There are 1024 Relu-activated dense layers and 256 dense layers using the sigmoid activation method. The hyper-parameters of the model, including the learning rate, batch size, epochs, and dropout rate, were tuned for the model. Next, three datasets of lung diseases were formed from separate open-access sources. One was a CT scan dataset containing 1043 images. Two X-ray datasets comprising images of COVID-19-affected lungs, pneumonia-affected lungs, and healthy lungs exist, with one being an imbalanced dataset with 5935 images and the other being a balanced dataset with 5002 images. The performance of each model was analyzed using the Adam, Nadam, and SGD optimizers. The best results have been obtained for both the CT scan and CXR datasets using the Nadam optimizer. For the CT scan images, LDDNet showed a COVID-19-positive classification accuracy of 99.36%, a 100% precision recall of 98%, and an F1 score of 99%. For the X-ray dataset of 5935 images, LDDNet provides a 99.55% accuracy, 73% recall, 100% precision, and 85% F1 score using the Nadam optimizer in detecting COVID-19-affected patients. For the balanced X-ray dataset, LDDNet provides a 97.07% classification accuracy. For a given set of parameters, the performance results of LDDNet are better than the existing algorithms of ResNet152V2 and XceptionNet

Automated Detection and Forecasting of COVID-19 using Deep Learning Techniques: A Review

Coronavirus, or COVID-19, is a hazardous disease that has endangered the health of many people around the world by directly affecting the lungs. COVID-19 is a medium-sized, coated virus with a single-stranded RNA. This virus has one of the largest RNA genomes and is approximately 120 nm. The X-Ray and computed tomography (CT) imaging modalities are widely used to obtain a fast and accurate medical diagnosis. Identifying COVID-19 from these medical images is extremely challenging as it is time-consuming, demanding, and prone to human errors. Hence, artificial intelligence (AI) methodologies can be used to obtain consistent high performance. Among the AI methodologies, deep learning (DL) networks have gained much popularity compared to traditional machine learning (ML) methods. Unlike ML techniques, all stages of feature extraction, feature selection, and classification are accomplished automatically in DL models. In this paper, a complete survey of studies on the application of DL techniques for COVID-19 diagnostic and automated segmentation of lungs is discussed, concentrating on works that used X-Ray and CT images. Additionally, a review of papers on the forecasting of coronavirus prevalence in different parts of the world with DL techniques is presented. Lastly, the challenges faced in the automated detection of COVID-19 using DL techniques and directions for future research are discussed

Applications of Artificial Intelligence in Battling Against Covid-19: A Literature Review

© 2020 Elsevier Ltd. All rights reserved.Colloquially known as coronavirus, the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), that causes CoronaVirus Disease 2019 (COVID-19), has become a matter of grave concern for every country around the world. The rapid growth of the pandemic has wreaked havoc and prompted the need for immediate reactions to curb the effects. To manage the problems, many research in a variety of area of science have started studying the issue. Artificial Intelligence is among the area of science that has found great applications in tackling the problem in many aspects. Here, we perform an overview on the applications of AI in a variety of fields including diagnosis of the disease via different types of tests and symptoms, monitoring patients, identifying severity of a patient, processing covid-19 related imaging tests, epidemiology, pharmaceutical studies, etc. The aim of this paper is to perform a comprehensive survey on the applications of AI in battling against the difficulties the outbreak has caused. Thus we cover every way that AI approaches have been employed and to cover all the research until the writing of this paper. We try organize the works in a way that overall picture is comprehensible. Such a picture, although full of details, is very helpful in understand where AI sits in current pandemonium. We also tried to conclude the paper with ideas on how the problems can be tackled in a better way and provide some suggestions for future works.Peer reviewe

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study

Introduction Patients presenting with acute undifferentiated breathlessness are commonly encountered in admissions units across the UK. Existing blood biomarkers have clinical utility in distinguishing patients with single organ pathologies but have poor discriminatory power in multifactorial presentations. Evaluation of volatile organic compounds (VOCs) in exhaled breath offers the potential to develop biomarkers of disease states that underpin acute cardiorespiratory breathlessness, owing to their proximity to the cardiorespiratory system. To date, there has been no systematic evaluation of VOC in acute cardiorespiratory breathlessness. The proposed study will seek to use both offline and online VOC technologies to evaluate the predictive value of VOC in identifying common conditions that present with acute cardiorespiratory breathlessness. Methods and analysis A prospective real-world observational study carried out across three acute admissions units within Leicestershire. Participants with self-reported acute breathlessness, with a confirmed primary diagnosis of either acute heart failure, community-acquired pneumonia and acute exacerbation of asthma or chronic obstructive pulmonary disease will be recruited within 24 hours of admission. Additionally, school-age children admitted with severe asthma will be evaluated. All participants will undergo breath sampling on admission and on recovery following discharge. A range of online technologies including: proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry and offline technologies including gas chromatography mass spectroscopy and comprehensive two-dimensional gas chromatography-mass spectrometry will be used for VOC discovery and replication. For offline technologies, a standardised CE-marked breath sampling device (ReCIVA) will be used. All recruited participants will be characterised using existing blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I and blood eosinophil levels and further evaluated using a range of standardised questionnaires, lung function testing, sputum cell counts and other diagnostic tests pertinent to acute disease. Ethics and dissemination The National Research Ethics Service Committee East Midlands has approved the study protocol (REC number: 16/LO/1747). Integrated Research Approval System (IRAS) 198921. Findings will be presented at academic conferences and published in peer-reviewed scientific journals. Dissemination will be facilitated via a partnership with the East Midlands Academic Health Sciences Network and via interaction with all UK-funded Medical Research Council and Engineering and Physical Sciences Research Council molecular pathology nodes. Trial registration number NCT0367299